Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Six Months Ended June 30, 2020 And Provide Corp...

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases,  announces 
that it will report its audited financial results for the three and six 
months ended June 30, 2020 on Friday, August 14, 2020 and host an 
investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to 
discuss these financial results and provide a corporate update. 
 
   To participate, please dial one of the following numbers and reference 
conference ID 4180419: 
 
 
   -- 877-870-9135 for callers in the United States 
 
   -- +44 800 279 6619 for international callers 
 
 
   A live webcast will be available on the Events and Presentations link on 
the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=r0xudaMzkAv_I3RmR-Dlqx94SUCyAHdQaT7t_PEyo8QwbzFj8cnLtfezprTWIkKxkISrWKFIDkxb8jlQyRfz5_R3O3OCZfDqh3M9pRzs1dc= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Following a response from 
the U.S. FDA to Verona Pharma's End-of-Phase 2 briefing package, the 
Company plans to initiate its  Phase 3 clinical program ENHANCE 
(Ensifentrine as a Novel inHAled Nebulized COPD thErapy) later in 2020 
for nebulized ensifentrine for COPD maintenance treatment. The Company 
raised gross proceeds of $200 million through a private placement in 
July 2020 and expects the funds to support its operations and Phase 3 
clinical program into 2023. Verona Pharma is currently in Phase 2 
development with two additional formulations of ensifentrine for the 
treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose 
inhaler. Ensifentrine also has potential applications in cystic fibrosis, 
asthma and other respiratory diseases. For more information, please 
visit www.veronapharma.com. 
 
 
 
 
 
Verona Pharma plc                                     Tel: +44 (0)20 3283 4200 
Victoria Stewart, Director of Communications          info@veronapharma.com 
 
N+1 Singer                                            Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
 Finance) 
Tom Salvesen (Corporate Broking) 
 
Optimum Strategic Communications                      Tel: +44 (0)20 950 9144 
 (European Media and Investor Enquiries)               verona@optimumcomms.com 
Mary Clark / Eva Haas / Shabnam Bashir 
 
Argot Partners                                        Tel: +1 212-600-1902 
 (US Investor Enquiries)                               verona@argotpartners.com 
Kimberly Minarovich / Michael Barron

(END) Dow Jones Newswires

July 30, 2020 02:00 ET (06:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024